{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.85","upperLimit":"0.95","value":"0.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"PPVs were calculated across the group on a per-region-basis on 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy and reported along with the corresponding two-sided 95% CIs. The CIs were constructed using the Wilson score method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Evaluate the PPV on a per-patient basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy","id":"OG000","title":"Pet Positive (Per Region)"}],"paramType":"NUMBER","populationDescription":"All subjects who received a 68Ga-PSMA-11 injection, had their 68Ga-PSMA-11 scan independently and blindly interpreted on a per region basis. Per region analyses included an evaluation of positive or negative for presence of PCa. Regional analyses included prostate bed, pelvic nodes, extrapelvic non-bone, and bone.","reportingStatus":"POSTED","timeFrame":"1 month","title":"Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation","type":"PRIMARY","unitOfMeasure":"percentage of times value is true"}